Immune Oncology Network Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT04144517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Immune Oncology Network

Active Ingredients

Drugs in Phase 2 Trials (2)

alks 4230 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2